Abstract
Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Graphical Abstract
Current Drug Safety
Title:A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal
Volume: 13 Issue: 3
Author(s): Rosa Lovero, Giuseppe Losurdo, Marcella Mastromauro, Nicola Maurizio Castellaneta, Antonio Mongelli, Antonietta Gentile, Alfredo Di Leo and Mariabeatrice Principi*
Affiliation:
- Section of Gastroenterology, Department of Emergency and Organ Transplantation, AOU Policlinico, University of Bari, Bari,Italy
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Abstract: Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Export Options
About this article
Cite this article as:
Lovero Rosa , Losurdo Giuseppe , Mastromauro Marcella , Castellaneta Maurizio Nicola , Mongelli Antonio , Gentile Antonietta , Di Leo Alfredo and Principi Mariabeatrice *, A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180719165212
DOI https://dx.doi.org/10.2174/1574886313666180719165212 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Relevance of CYP2C9 Function in Valproate Therapy
Current Neuropharmacology Meet Our Editorial Board Member
Applied Clinical Research, Clinical Trials and Regulatory Affairs Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Current Alzheimer Research Potential Genetic Therapies for Acute Lung Injury
Current Gene Therapy Continuous Elevation of Intracellular Ca2+ Is Essential for the Development of Cerebral Vasospasm
Current Vascular Pharmacology An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Current Drug Safety The Role of the Chaperone Grp94/Gp96 in the Intestinal Barrier and Innate Immune Functions
Current Immunology Reviews (Discontinued) PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design MicroRNAs in Arterial Remodelling, Inflammation and Atherosclerosis
Current Drug Targets Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets